Aminoglycosides are the mainstay in the treatment of serious gram negative infections including catheter-associated infections. They are not metabolized and are rapidly excreted as such by glomerular filtration resulting in a plasma t(½) of approximately two hours in those with normal renal function. The t(½), however, can extend to 30-60 hours in patients who are functionally anephric; therefore, dosage reduction or modification is necessary in renal failure patients. In patients on hemodialysis the clearance of aminoglycosides is significant and variable. The concept of conventional postdialysis dosing in patients on hemodialysis needs to be revised in favor of higher predialysis doses to maintain effective bactericidal activity. This article is a brief review of the use of aminoglycosides in renal failure patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966976 | PMC |
http://dx.doi.org/10.4103/0971-4065.70839 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!